PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and ...

in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A ...

The presented posters “ Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations ” and “ ...

The plan was to access new federal and state subsidies for microchip and climate change/green energy-related industries ... a 1,260-acre Science, Technology and Advanced Manufacturing Park ...

A poster of Hezbollah leader Sayyed Hassan Nasrallah is placed ... It was unclear how far the alleged plot had advanced. The ...

Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 ...

Uttarakhand Chief Minister Pushkar Singh Dhami took part at an event held at the Mukhya Sevak Sadan in the Chief Minister ...

Event at Bustleton Library Bustleton Library, 10199 Bustleton Ave., will host a visit by the city Department of Public Health ...

David Pittman (left), who directs the Engineer Research and Development Center (ERDC) for the U.S. Army Corps of Engineers, ...